InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Roundtable: The second medical use challenge – full transcript

James Nurton, London


Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London

This is the full, unabridged, transcript of the discussion, which was held on January 18 this year at the office of Bristows in London, and was moderated by Managing IP’s James Nurton. The views expressed are those of the participants...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Useful article on this week's webinar on geographic names and #TLDs - of interest to trademark folk. https://t.co/rWw0AMlxYJ

Apr 27 2017 03:42 ·  reply ·  retweet ·  favourite
ManagingIP profile

Our ed James Nurton is moderating a panel at Superyacht Investor @syinvestor next week. Say hello if you're there!… https://t.co/l90ccpHAXd

Apr 27 2017 03:19 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @uspto: Co-founder of @gogritorg demonstrated how innovation improves lives at USPTO's #WorldIPDay event. Read the #blog: https://t.co/m

Apr 27 2017 03:14 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


April 2017

Patent subject matter eligibility: A new Section 101

Calls for changing Section 101 of the Patent Act in the US are increasing. A proposed amendment from IPO shows one way to do it, reports Michael Loney



Most read articles

Supplements